A Phase 4 interventional study of Semaglutide Injectable Product and Lifestyle Counseling in Aging, Diabetes Mellitus, Type 2 and PreDiabetes, sponsored by The University of Texas Health Science Center at San Antonio. Completed at 1 site in United States. Open to participants aged 65 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-05-04.
Sponsored by The University of Texas Health Science Center at San Antonio · Phase 4, Interventional, and Basic science
Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects, semaglutide has on people who take the drug and the drug's effect on physical function, body composition, and aging.
3,670 studies on the registry are indexed under Overweight; 849 are open to participants now.
This study's enrollment of 20 is below the median of 73 across 3,175 interventional studies indexed under Overweight.
Browse Overweight studies →The University of Texas Health Science Center at San Antonio is the lead sponsor of 435 studies on the registry; 88 are open to participants now.
Of its 62 completed or terminated interventional studies of FDA-regulated products, 31 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants will meet with a dietician throughout the study to discuss lifestyle counseling based on recommendation in the diabetes prevention program. They will also be given semaglutide for 20 weeks.
Drug: Semaglutide Injectable Product · Behavioral: Lifestyle Counseling
Participants will meet with a dietician throughout the study to discuss lifestyle counseling based on recommendation in the diabetes prevention program
Behavioral: Lifestyle Counseling
Semaglutide will be started at 0.25mg once a week for 4 weeks followed by 0.5mg once weekly for 4 weeks followed by 1.0mg once a week for 12 weeks.
Also known as: Semaglutide and Lifestyle Counseling
Lifestyle Counseling will be provided throughout study intervention
Lean Body Mass Change
Determine if there is any change in lean body mass
Time frame: Baseline to 20 weeks
| Milestone | Semaglutide and Lifestyle Intervention | Lifestyle Intervention |
|---|---|---|
| Started | 10 | 10 |
| Completed | 10 | 10 |
| Not completed | 0 | 0 |
Determine if there is any change in lean body mass
| g | Semaglutide and Lifestyle Intervention | Lifestyle Intervention |
|---|---|---|
| Lean Body Mass Change | -1730.6 (-3063 to -398) | -421 (-1745 to 911) |
Collected over 20 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Semaglutide and Lifestyle Intervention | 0/10 (0%) | 0/10 (0%) | 6/10 (60%) |
| Lifestyle Intervention | 0/10 (0%) | 0/10 (0%) | 1/10 (10%) |
| Event | Semaglutide and Lifestyle Intervention | Lifestyle Intervention |
|---|---|---|
| Abdominal painGastrointestinal disorders | 6/10 | 1/10 |
| Age, Categorical(Participants) | Semaglutide and Lifestyle Intervention | Lifestyle Intervention | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 10 | 10 | 20 |
| Age, Continuous(years) | Semaglutide and Lifestyle Intervention | Lifestyle Intervention | Total |
|---|---|---|---|
| Mean | 71.9 ± 4.85 | 73.4 ± 4.98 | 72.65 ± 4.85 |
| Sex: Female, Male(Participants) | Semaglutide and Lifestyle Intervention | Lifestyle Intervention | Total |
|---|---|---|---|
| Female | 5 | 5 | 10 |
| Male | 5 | 5 | 10 |
| Ethnicity (NIH/OMB)(Participants) | Semaglutide and Lifestyle Intervention | Lifestyle Intervention | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 4 | 9 |
| Not Hispanic or Latino | 5 | 6 | 11 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Semaglutide and Lifestyle Intervention | Lifestyle Intervention | Total |
|---|---|---|---|
| United States | 10 | 10 | 20 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The University of Texas Health Science Center at San Antonio